Analysis of cancer mutation signatures in blood by a novel ultra-sensitive assay: Monitoring of therapy or recurrence in non-metastatic breast cancer

PLoS ONE

Volumn 4, Issue 9, 2009, Pages

  Chen, Zhenbin ^a   Feng, Jinong ^a   Buzin, Carolyn H ^a,b   Liu, Qiang ^a   Weiss, Lawrence ^a   Kernstine, Kemp ^a   Somlo, George ^a   Sommer, Steve S ^a,b  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b MEDomics   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN P53; DNA; PRIMER DNA; TUMOR MARKER;

ALLELE; ANALYTIC METHOD; ANIMAL TISSUE; ARTICLE; BLOOD SAMPLING; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER GROWTH; CANCER RECURRENCE; CANCER REGRESSION; CANCER STAGING; CANCER THERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE AMPLIFICATION; GENE DELETION; GENE INSERTION; GENE MUTATION; GENETIC ANALYSIS; HUMAN; HUMAN TISSUE; LUNG CANCER; MONITORING; MULTIPLE CYCLE TREATMENT; NONHUMAN; NUCLEOTIDE SEQUENCE; POLYMERIZATION; RAT; SOMATIC MUTATION; ANIMAL; BLOOD; BREAST TUMOR; CHEMISTRY; GENETICS; METABOLISM; METASTASIS; METHODOLOGY; NEOPLASM; PATHOLOGY; PHOSPHORYLATION; RECURRENT DISEASE; SENSITIVITY AND SPECIFICITY; TUMOR EMBOLISM;

ANIMALS; BREAST NEOPLASMS; DNA; DNA MUTATIONAL ANALYSIS; DNA PRIMERS; FEMALE; HUMANS; NEOPLASM METASTASIS; NEOPLASMS; NEOPLASTIC CELLS, CIRCULATING; PHOSPHORYLATION; RATS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECURRENCE; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 70349696342     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0007220     Document Type: Article

References (40)

1. Bielas JH, Loeb KR, Rubin BP, True LD, Loeb LA (2006) Human cancers express a mutator phenotype. Proc Natl Acad Sci U S A 103: 18238-18242.
2. Huse SM, Huber JA, Morrison HG, Sogin ML, Welch DM (2007) Accuracy and quality of massively parallel DNA pyrosequencing. Genome Biol 8: R143.
3. Li M, Diehl F, Dressman D, Vogelstein B, Kinzler KW (2006) BEAMing up for detection and quantification of rare sequence variants. Nat Methods 3: 95-97.
4. Parsons BL, Heflich RH (1998) Detection of basepair substitution mutation at a frequency of 1×10(-7) by combining two genotypic selection methods, MutEx enrichment and allele-specific competitive blocker PCR. Environmental and Molecular Mutagenesis 32: 200-211.
5. Pao W, Ladanyi M (2007) Epidermal growth factor receptor mutation testing in lung cancer: searching for the ideal method. Clin Cancer Res 13: 4954-4955.
6. Mitani Y, Lezhava A, Kawai Y, Kikuchi T, Oguchi-Katayama A, et al. (2007) Rapid SNP diagnostics using asymmetric isothermal amplification and a new mismatch-suppression technology. Nat Methods 4: 257-262.
7. Liu Q, Sommer SS (2004) PAP: detection of ultra rare mutations depends on P* oligonucleotides: "sleeping beauties" awakened by the kiss of pyrophosphorolysis. Hum Mutat 23: 426-436.
8. Liu Q, Sommer SS (2004) Detection of extremely rare alleles by bidirectional pyrophosphorolysis-activated polymerization allele-specific amplification (Bi-PAP-A): measurement of mutation load in mammalian tissues. BioTechniques 36: 156-166.
9. Shi J, Liu Q, Sommer SS (2007) Detection of ultrarare somatic mutation in the human TP53 gene by bidirectional pyrophosphorolysis-activated polymerization allele-specific amplification. Hum Mutat 28: 131-136.
10. Gu D, Scaringe WA, Li K, Saldivar JS, Hill KA, et al. (2007) Database of somatic mutations in EGFR with analyses revealing indel hotspots but no smoking-associated signature. Hum Mutat 28: 760-770.
11. Chen Z, Feng J, Saldivar JS, Gu D, Bockholt A, et al. (2008) EGFR somatic doublets in lung cancer are frequent and generally arise from a pair of driver mutations uncommonly seen as singlet mutations: one-third of doublets occur at five pairs of amino acids. Oncogene 27: 4336-4343.
12. Buettner VL, Hill KA, Halangoda A, Sommer SS (1999) Tandem-base mutations occur in mouse liver and adipose tissue preferentially as G:C to T:A transversions and accumulate with age. EnvironMol Mutagen 33: 320-324.
13. Hill KA, Wang J, Farwell KD, Sommer SS (2003) Spontaneous tandem-base mutations (TBM) show dramatic tissue, age, pattern and spectrum specificity. Mutation Research 534: 173-186.
14. Wang J, Gonzalez KD, Scaringe WA, Tsai K, Liu N, et al. (2007) Evidence for mutation showers. ProcNatlAcadSciUS A 104: 8403-8408.
15. Liu Q, Sommer SS (2002) Pyrophosphorolysis-activatable oligonucleotides may facilitate detection of rare alleles, mutation scanning and analysis of chromatin structures. Nucleic Acids Res 30: 598-604.
16. Sarkar G, Sommer SS (1990) The "megaprimer" method of site-directed mutagenesis. BioTechniques 8: 404-407.
17. Saldivar JS, Chen Z, Sommer SS, Haines JL, Korf BR, et al. (2006) EGF Receptor Testing for Non-Small Cell Lung Carcinomas. Current Protocols in Human Genetics: John Wiley & Sons, Inc. pp 10.19.14-10.19.14.
18. Kwok S, Higuchi R (1989) Avoiding false positives with PCR. Nature 339: 237-238.
19. Sarkar G, Sommer SS (1990) Shedding light on PCR contamination. Nature 343: 27.
20. Zheng L, Dai H, Zhou M, Li M, Singh P, et al. (2007) Fen1 mutations result in autoimmunity, chronic inflammation and cancers. Nat Med 13: 812-819.
21. Bell DW, Gore I, Okimoto RA, Godin-Heymann N, Sordella R, et al. (2005) Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR. NatGenet 37: 1315-1316.
22. Song W, Li W, Feng J, Heston LL, Scaringe WA, et al. (2008) Identification of high risk DISC1 structural variants with a 2% attributable risk for schizophrenia. Biochem Biophys Res Commun 367: 700-706.
23. Fleischhacker M, Schmidt B (2007) Circulating nucleic acids (CNAs) and cancer-a survey. BiochimBiophys Acta 1775: 181-232.
24. Gormally E, Caboux E, Vineis P, Hainaut P (2007) Circulating free DNA in plasma or serum as biomarker of carcinogenesis: practical aspects and biological significance. MutatRes 635: 105-117.
25. Halangoda A, Still JG, Hill KA, Sommer SS (2001) Spontaneous microdeletions and microinsertions in a transgenic mouse mutation detection system: analysis of age, tissue, and sequence specificity. Environ Mol Mutagen 37: 311-323.
26. Greaves M (2007) Darwinian medicine: a case for cancer. Nat Rev Cancer 7: 213-221.
27. Sommer SS (1994) Does cancer kill the individual and save the species? Human Mutation 3: 166-169.
28. Vineis P, Berwick M (2006) The population dynamics of cancer: a Darwinian perspective. Int J Epidemiol 35: 1151-1159.
29. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, et al. (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J NatlCancer Inst 92: 205-216.
30. Hartmann A, Blaszyk H, Kovach JS, Sommer SS (1997) The molecular epidemiology of p53 gene mutations in human breast cancer. Trends in Genetics 13: 27-33.
31. Kovach JS, McGovern RM, Cassady JD, Swanson SK, Wold LE, et al. (1991) Direct sequencing from touch preparations of human carcinomas: analysis of p53 mutations in breast carcinomas. Journal of National Cancer Institute 83: 1004-1009.
32. Bellus GA, Hefferon TW, Ortiz dLRI, Hecht JT, Horton WA, et al. (1995) Achondroplasia is defined by recurrent G380R mutations of FGFR3. Am J Hum Genet 56: 368-373.
33. Buzin CH, Feng J, Yan J, Scaringe W, Liu Q, et al. (2005) Mutation rates in the dystrophin gene: a hotspot of mutation at a CpG dinucleotide. Hum Mutat 25: 177-188.
34. Moloney DM, Slaney SF, Oldridge M, Wall SA, Sahlin P, et al. (1996) Exclusive paternal origin of new mutations in Apert syndrome. Nature Genetics 13: 48-53.
35. Liu Q, Nguyen VQ, Li X, Sommer SS (2006) Multiplex dosage pyrophosphorolysis-activated polymerization: application to the detection of heterozygous deletions. BioTechniques 40: 661-668.
36. Shigematsu H, Gazdar AF (2005) Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers. IntJ Cancer 118: 257-262.
37. Port JL, Kent MS, Korst RJ, Libby D, Pasmantier M, et al. (2003) Tumor size predicts survival within stage IA non-small cell lung cancer. Chest 124: 1828-1833.
38. Birim O, Kappetein AP, Takkenberg JJ, van Klaveren RJ, Bogers AJ (2005) Survival after pathological stage IA nonsmall cell lung cancer: tumor size matters. AnnThoracSurg 79: 1137-1141.
39. Martini N, Bains MS, Burt ME, Zakowski MF, McCormack P, et al. (1995) Incidence of local recurrence and second primary tumors in resected stage I lung cancer. J ThoracCardiovascSurg 109: 120-129.
40. Diehl F, Schmidt K, Choti MA, Romans K, Goodman S, et al. (2008) Circulating mutant DNA to assess tumor dynamics. Nat Med 14: 985-990.